Agios Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian Goff
- Full Time Employees
- 540
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 88 Sidney Street Cambridge MA United States of America 02139-4169
- IPO Date
- Jul 24, 2013
- CIK
- 0001439222
- Website
- agios.com
- Similar Companies
- Business
- Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing transformative therapies primarily in the field of cellular metabolism, with a near-term emphasis on rare diseases such as hemolytic and acquired anemias. Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios develops precision medicines including its flagship product, Pyrukynd (mitapivat), an oral activator of pyruvate kinase enzymes targeting hemolytic anemias such as pyruvate kinase deficiency and sickle cell disease. Its product portfolio also involves investigational candidates like tebapivat, a next-generation PK activator, and AG-236, aimed at addressing broader metabolic and hematologic disorders. The company’s offerings encompass small-molecule drugs and supportive patient services programs like myAgios to facilitate access and treatment adherence. Recent major developments include the positive results from the ACTIVATE-Kids Phase 3 study demonstrating the efficacy of mitapivat in pediatric patients with pyruvate kinase deficiency, establishing a pathway for pediatric label expansion. Agios is preparing for the U.S. commercial launch of Pyrukynd in multiple hemolytic anemia indications including sickle cell disease and thalassemia in 2026, supported by increased commercial infrastructure and headcount expansion. The company is advancing pipeline diversification with an IND filing planned for mid-2025 for AG-236 and Phase 2 trials for tebapivat in sickle cell disease, reinforcing its strategic objective to treat a broad spectrum of rare blood disorders through oral, disease-modifying therapies. Agios also concentrates on expanding its research into cancer metabolism as a complementary segment. Agios Pharmaceuticals operates primarily in the United States with its products addressing unmet needs in the rare genetic disease market and hematology segments. It leverages advanced technologies in metabolic pathway targeting, small molecule drug discovery, and clinical development. The company’s strategic alliances, regulatory progress, and patient-centric commercialization programs position it as a leader in the transformative rare disease therapy space. Its founding scientific focus on cellular metabolism continues to drive innovation across both rare hematologic diseases and oncology therapeutic areas. This comprehensive portfolio and recent clinical and commercial advances underline Agios’s commitment to providing long-term, disease-modifying treatments for patients with rare metabolic diseases and blood disorders.
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Agios Pharma to discontinue sickle cell disease treatment development
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
AGIO Stock Surges 35% in Six Months: What's Driving It?
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?